Avrobio Overview

  • Founded
  • 2015
Founded
  • Status
  • Public
  • Employees
  • 121
Employees
  • Stock Symbol
  • AVRO
Stock Symbol
  • Share Price
  • $8.75
  • (As of Thursday Closing)

Avrobio General Information

Description

Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single dose treatment regimen. The company's pipeline includes AVR-RD-01, AVR-RD-02, AVR-RD-03, and AVR-RD-04 which are used for various diseases such as Fabry, Gaucher, Pompe, and Cystinosis.

Contact Information

Website
www.avrobio.com
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Stock Exchange
NAS
Primary Office
  • One Kendall Square
  • Building 300, Suite 201
  • Cambridge, MA 02139
  • United States
+1 (617) 000-0000

Avrobio Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Avrobio Stock Performance

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$8.75 $8.72 $8.50 - $23.50 $365M 41.8M 716K -$3.31

Avrobio Financials Summary

In Thousands,
USD
TTM 31-Dec-2020 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 358,280 358,280 431,113 260,288
Revenue 0 0 0 0
EBITDA (119,224) (119,224) (75,049) (47,707)
Net Income (119,712) (119,712) (72,965) (46,361)
Total Assets 271,234 271,234 200,514 133,479
Total Debt 0 0 0 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Avrobio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Avrobio‘s full profile, request access.

Request a free trial

Avrobio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Avrobio‘s full profile, request access.

Request a free trial

Avrobio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Avrobio Inc is a clinical-stage gene therapy company. It is engaged in developing potentially curative ex vivo lentivira
Biotechnology
Cambridge, MA
121 As of 2020
00000
000000 - 000 00000

00000 00

im ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequa
0000 000000000
Watertown, MA
000 As of 0000
00.000
00000000 00.000

0000 000

nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit
0000000000000
Santa Monica, CA
000 As of 0000
00000
000 0000-00-00
000000&0 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Avrobio Competitors (61)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Forma Therapeutics Formerly VC-backed Watertown, MA 000 00.000 00000000 00.000
0000 000000 Formerly VC-backed Santa Monica, CA 000 00000 000000&0 00000
0000000 0000000000 Formerly PE-Backed Cambridge, MA 000 00000 000000000
00000000 000000000 Formerly VC-backed Cambridge, MA 000 0000 000000 - 000 0000
00 00000000 Venture Capital-Backed Glasgow, United Kingdom 00 000.00 000000000000 000.00
You’re viewing 5 of 61 competitors. Get the full list »

Avrobio Executive Team (12)

Name Title Board Seat Contact Info
Steven Avruch JD Chief Legal Officer
Holly May Chief Commercial Officer
Kim Raineri Chief Manufacturing and Technology Officer
Deanna Petersen Executive
Jeffrey Medin Ph.D Co-Founder
You’re viewing 5 of 12 executive team members. Get the full list »

Avrobio Board Members (10)

Name Representing Role Since
Annalisa Jenkins Self Board Member 000 0000
Bruce Booth Ph.D Atlas Venture Chairman & Board Member 000 0000
Christopher Paige Ph.D Avrobio Board Member 000 0000
Gail Farfel Ph.D Self Board Member 000 0000
Geoff MacKay Self Chief Executive Officer, President & Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

Avrobio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Avrobio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Avrobio‘s full profile, request access.

Request a free trial